Market news

MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. Sight Sciences’ management is scheduled to present on Tuesday, September 15, 2026, at 6:15 am

Detailed price information for Sight Sciences Inc (SGHT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Sight Sciences Inc (SGHT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Sight Sciences (SGHT) has an average rating of overweight and mean price target of $8.60, according

The fair value estimate for Sight Sciences has shifted from US$9.35 to US$8.40, pointing to a more measured central valuation in the latest update. This adjustment lines up with recent Street research, where some analysts have trimmed targets and leaned on more cautious assumptions even as interest in the eyecare sector remains. In the following sections, you will see how these changing views, and the updated guidance, shape the evolving Sight Sciences narrative and what that might mean for...

Sight Sciences (SGHT) delivered earnings and revenue surprises of +46.67% and +7.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense GuidanceMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2026, raised its revenue guidance and reduced its ad

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eyecare and improve patients’ lives, today announced that Aetna, Inc.’s (Aetna) updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI® Surgical System (OMNI) and the SION® Surgical Instrument (SION) as medically nece

Sight Sciences (NASDAQ:SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjus

New system expands the Company’s leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform eye care and improve patients' lives, today announced U.S. Food and Drug Administration (FDA) 510(k) cleara

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Sight Sciences (SGHT) has an average rating of overweight and mean price target of $8.40, according

MENLO PARK, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2026, after the market close on Wednesday, August 5, 2026. The Company’s management will discuss the results during a conf